Table 3.

Study endpoints.

A
	Study variables
Study outcomes	MS (n 99)	No MS (n 107)	P-value	ICD-VVI (n 57)	ICD-DDD (n 151)	P-value
All cause deaths (%)	8 (8.1)	7 (6.5)	n.s.	4 (7)	11 (7.2)	n.s.
Cardiac deaths (%)	3 (3.1)	5 (4.7)	n.s.	2 (3.5)	6 (3.9)	n.s.
Hospitalization for heart failure (%)	24 (24.2)	13 (12.1)	0.04*	11 (19.2)	26 (17.2)	n.s.
Appropriate therapy (%)	26 (26.3)	41 (38.3)	0.05*	20 (35)	47 (31.1)	n.s.
Inappropriate therapy (%)	27 (27.3)	18 (16.8)	0.05*	13 (22.8)	32 (21.2)	n.s.
Survival after appropriate therapy (%)	21 (21.2)	35 (32.7)	0.05*	17 (29.8)	39 (25.8)	n.s.
B
	Study variables
Study outcomes	ST2 (mean value)	ST2 I	ST2 II	ST2 III	ST2 IV	P-value
All cause deaths. n 15 (%)	98.73 [23.75-203.73]	1	2	4	8	< 0.05*. **
Cardiac deaths. n 8 (%)	101.34 [23.75-203.73]	1	1	3	3	< 0.05*
Hospitalization for heart failure. n 37 (%)	140.83 [23.75-263]	4	7	10	16	< 0.05*. **. ***
Appropriate therapy. n 67 (%)	128.92 [23.51-291.31]	6	12	18	31	< 0.05*. **. ***
Inappropriate therapy. n 45 (%)	166.60 [24.24-282]	2	5	8	30	< 0.05*. **. ***
Survival after appropriate therapy. n 56 (%)	30.68 [16.48-82.05]	20	16	11	9	< 0.05°. °°

A. In this table we reported number of events of the study outcomes experienced in Metabolic Syndrome (MS) vs. controls (no MS), and in internal cardioverter defibrillator single chamber (ICD-VVI) vs. internal cardioverter defibrillator dual chambers (ICD-DDD). The symbol ^* marked a p < 0.05 comparing MS vs. no MS; the symbol ^** marked a p < 0.05 comparing ICD-VVI vs. ICD-DDD.

B. In this table number of events of the study outcomes experienced in the ST2 protein quartiles (Ith, IIth, IIIth, and IVth quartile) in ng/ml (see the text). A p < 0.05 is marked with symbol:

^*if ST2 IVth vs. ST2 Ith;

^**if ST2 IVth vs. ST2 IIIth;

^***if ST2 IVth vs. ST2 IIth;

^°if ST2 Ith vs. ST2 IVth;

^°°if ST2 Ith vs. ST2 IIIth.